Number of Participants With AEs, Serious AEs (SAE) and Adverse Event of Special Interest (AESI) Occurring Post Each Dose of Study Vaccination;Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters;Number of Participants With Local Solicited Adverse Events (AE);Number of Participants With Systemic Solicited AEs;Percentage of Participants With Seroresponse to the Spike (S) Antigen of AZD1222 as Measured by Meso Scale Discovery (MSD) Serology Assay

Number of Participants With AEs, Serious AEs (SAE) and Adverse Event of Special Interest (AESI) Occurring Post Each Dose of Study Vaccination;Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters;Number of Participants With Local Solicited Adverse Events (AE);Number of Participants With Systemic Solicited AEs;Percentage of Participants With Seroresponse to the Spike (S) Antigen of AZD1222 as Measured by Meso Scale Discovery (MSD) Serology Assay

The incidence of local and systemic solicited reactogenicity signs and symptoms for 7 days following throughout vaccination;The incidence of local and systemic solicited reactogenicity signs and symptoms for 7 days following throughout vaccination;Haematology; change from baseline for hematology/hemostasis measures;Proportion of participants who have a post treatment seroresponse to the spike antigens of AZD1222;Biochemistry; change from baseline for blood chemistry measures;The incidence of AEs, serious adverse events (SAEs) and adverse events of special interest (AESIs)

The incidence of local and systemic solicited reactogenicity signs and symptoms for 7 days following throughout vaccination;The incidence of local and systemic solicited reactogenicity signs and symptoms for 7 days following throughout vaccination;Haematology; change from baseline for hematology/hemostasis measures;Proportion of participants who have a post treatment seroresponse to the spike antigens of AZD1222;Biochemistry; change from baseline for blood chemistry measures;The incidence of AEs, serious adverse events (SAEs) and adverse events of special interest (AESIs)

The incidence of local and systemic solicited reactogenicity signs and symptoms for 7 days following throughout vaccination;Proportion of participants who have a post treatment seroresponse;The incidence of local and systemic solicited reactogenicity signs and symptoms for 7 days following throughout vaccination;Haematology; change from baseline for hematology/hemostasis measures;Biochemistry; change from baseline for blood chemistry measures;The incidence of AEs, serious adverse events (SAEs) and adverse events of special interest (AESIs)

The incidence of local and systemic solicited reactogenicity signs and symptoms for 7 days following throughout vaccination;Proportion of participants who have a post treatment seroresponse;The incidence of local and systemic solicited reactogenicity signs and symptoms for 7 days following throughout vaccination;Haematology; change from baseline for hematology/hemostasis measures;Biochemistry; change from baseline for blood chemistry measures;The incidence of AEs, serious adverse events (SAEs) and adverse events of special interest (AESIs)